Skip to main content

Table 1 Patients’ characteristics and distribution of clinical parameters according to individual preference, n = 119

From: Preference of elderly patients’ to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trial

Parameter of disease (n, %) Preference to treatment
i.v. (n = 102) oral (n = 17)
Median age, in years (range) 72 (65–87) 70 (65–77)
ECOG
 0 22 (21.6) 4 (23.5)
 1 68 (66.7) 10 (58.8)
 2 12 (11.7) 3 (17.7)
FIGO stage at primary diagnosis
 I 2 (2) 1 (5.9)
 II 7 (6.9) 1 (5.9)
 III 62 (60.8) 13 (76.5)
 IV 25 (24.5) 2 (11.7)
 not documented 6 (5.9) -
Histology
 Serous papillary 59 (57.8) 13 (76.5)
 Mucinous 12 (11.7) 3 (17.7)
 Endometrioid 8 (7.8) 1 (5.9)
 Others or NOS 23 (22.6) -
Grading at primary diagnosis
 G1 2 (2) -
 G2 29 (28.4) 5 (29.4)
 G3 61 (59.8) 12 (70.6)
 not documented 10 (9.8) -
Type of treatment in the adjuvant situation or last recurrence
 Surgical tumordebulking 100 (98) 17 (100)
 Chemotherapy 101 (99) 17 (100)
 Previous hormonal treatment 8 (7.8) 2 (11.8)
 Previous Radiotherapy 6 (5.9) 1 (5.9)
Relapse-free interval after primary platinum based therapy
  < 6 months 21 (20.6) 4 (23.5)
 6–12 months 28 (27.5) 7 (41.2)
  > 12 months 53 (51.9) 6 (35.3)
Type of previous chemotherapy regimens (n = 372)
 platinum/taxan based 182 (56.9) 22 (44.9)
 anthracyclin 38 (11.9) 6 (12.2)
 topotecan 45 (14) 9 (18.4)
 taxan 12 (3.8) 1 (2.1)
 others 43 (13.4) 11 (22.4)
No. of previous chemotherapies for all median (min. / max.) 3 (1–8)
  3 (1–8) 2 (1–7)
Recurrent situation at time of registration
 1. Recurrence 13 (12.7) 1 (5.9)
 2. Recurrence 25 (24.5) 8 (47)
 3. Recurrence 30 (29.4) 4 (23.5)
 4. Recurrence 15 (14.7) 2 (11.8)
  > 4 Recurrencies 19 (18.6) 2 (11.8)